What Is RU-58841? Dosage, Half-Life & How to Track It

What RU-58841 is and how it works — and what it is not

RU-58841 was originally developed by Roussel-Uclaf as a topical antiandrogen candidate for acne and hair loss. Its mechanism is straightforward: it binds androgen receptors in the hair follicle and competitively blocks dihydrotestosterone (DHT) — the hormone primarily responsible for the follicle miniaturization seen in androgenetic (male- and female-pattern) hair loss — from activating them there.

This is worth stating plainly because the name gets confused with a different category of compound: RU-58841 is not a SARM. SARMs (selective androgen receptor modulators) are designed to *activate* androgen receptors in muscle and bone for performance or body-composition purposes, taken systemically. RU-58841 does the opposite — it *blocks* the receptor, and it is designed to work locally on the scalp, not systemically. Conflating the two is a common but meaningful error.

It never completed clinical development or received regulatory approval anywhere, and Roussel-Uclaf's hair-loss program did not proceed to market — for reasons that are not fully public but likely included the broader difficulty and cost of topical-antiandrogen development at the time. It has since circulated as a compounded/research topical, most often alongside minoxidil in DIY hair-loss regimens, with human evidence limited mostly to small studies and long-running anecdotal community use rather than large controlled trials.

Typical application

RU-58841 is not reconstituted from a lyophilized vial the way an injectable peptide is — it is compounded into a topical solution, commonly cited around 5% concentration in a propylene-glycol-based vehicle, and applied directly to the scalp (usually the areas showing thinning) once or twice daily. Some formulations are combined with minoxidil in the same solution; others are applied separately to avoid interaction at the applicator.

Because it is designed to act at the follicle rather than systemically, there is no unit-dose or reconstitution-math question the way there is for an injectable — the practical tracking need is application consistency: whether the scalp application happened on schedule, since topical antiandrogen regimens for hair loss generally need months of consistent use before a trend is visible.

Absorption & what it means for frequency

RU-58841's design goal is minimal systemic absorption when applied topically as intended — the whole point of a topical antiandrogen over an oral one (like finasteride) is to block DHT at the follicle without meaningfully lowering androgen activity elsewhere in the body, which is the source of finasteride's more discussed systemic side effects.

That local-action design is why it is applied on a fixed daily-to-twice-daily schedule directly to the scalp rather than dosed by body weight or blood level — the relevant "half-life" question is less about systemic clearance and more about how long the compound persists at the follicle after each application, which has not been rigorously characterized in humans.

What to track & common side effects

The most commonly reported issues are local: scalp irritation, dryness, or contact dermatitis at the application site, particularly with higher concentrations or the propylene-glycol vehicle itself (some people react to the vehicle, not the active compound). Because systemic absorption is intended to be minimal, the systemic antiandrogen effects associated with oral finasteride are not expected — but human safety data at this scale of long-term use is thinner than for an approved drug, so that is inferred from the design, not proven by large trials.

What is worth tracking is straightforward: application consistency (once vs twice daily, and whether it actually happened), any scalp irritation, and — since hair-loss treatments are judged over months, not days — periodic photos of the treated area, since day-to-day changes are invisible and the real signal is the multi-month trend.

Frequently asked questions